Lipocine Inc. (LPCN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LPCN Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for LPCN is 0.01 -- better than merely 9.18% of US stocks.
- LPCN's price/sales ratio is 568.42; that's higher than the P/S ratio of 99.01% of US stocks.
- The volatility of Lipocine Inc's share price is greater than that of 92.61% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Lipocine Inc are ONCT, ETON, HTBX, QUIK, and CDXS.
- LPCN's SEC filings can be seen here. And to visit Lipocine Inc's official web site, go to www.lipocine.com.
LPCN Stock Price Chart Interactive Chart >
LPCN Price/Volume Stats
|Current price||$1.33||52-week high||$2.42|
|Prev. close||$1.25||52-week low||$0.82|
|Day high||$1.35||Avg. volume||3,360,074|
|50-day MA||$1.38||Dividend yield||N/A|
|200-day MA||$1.50||Market Cap||117.43M|
Lipocine Inc. (LPCN) Company Bio
Lipocine develops pharmaceutical products using its oral drug delivery technology in the areas of mens and womens health, with a current focus being testosterone replacement. The company was founded in 1997 and is based in Salt Lake City, Utah.
LPCN Latest News Stream
|Loading, please wait...|
LPCN Latest Social Stream
View Full LPCN Social Stream
Latest LPCN News From Around the Web
Below are the latest news stories about Lipocine Inc that investors may wish to consider to help them evaluate LPCN as an investment opportunity.
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Lytham Partners Summer 2021 Investor Conference. The conference will be held virtually. Presentation details are below.
By John Vandermosten, CFA NASDAQ:LPCN Hopes for Lipocine Inc. (NASDAQ:LPCN) to secure damages from Clarus related to the ongoing patent infringement lawsuit patents faded on Tuesday. On May 25, the US District Court for the District of Delaware granted Clarus Therapeutics a motion for summary judgment against the patents in the suit advanced by Lipocine in the patent infringement case. Judge
The U.S. District Court of Delaware has granted Clarus Therapeutics' motion for summary judgment against Lipocine (LPCN) for failure to provide adequate written description of Lipocine's asserted patent claims.In his decision, which gives Clarus an unequivocal win, Judge William C. Bryson found all of the asserted Lipocine patent claims invalid.Clarus's...
Good morning, investors!
The U.S. District Court for the District of Delaware has granted Clarus Therapeutics' motion for summary judgment against remaining patents in a patent infringement case brought by Lipocine Inc (NASDAQ: LPCN) regarding Clarus's oral testosterone replacement product, Jatenzo. Federal Circuit Judge found all of the asserted Lipocine patents claims invalid. Clarus's defense of inequitable conduct remains pending, and its disposition is expected to be addressed by Clarus and the Court at a future date. Lipocine brought the action for patent infringement against Clarus in April 2019, arising out of Clarus's marketing of Jatenzo, an oral testosterone replacement product approved by the FDA in March 2019 and launched in March 2020. Price Action: LPCN shares are down 13.7% at $1.18 during the m...
LPCN Price Returns